Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Status:
Completed
Trial end date:
2018-04-23
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well trametinib and v-akt murine thymoma viral oncogene
homolog 1 (Akt) inhibitor GSK2141795 work in treating patients with triple-negative breast
cancer (breast cancer cells that do not have estrogen receptors, progesterone receptors, or
large amounts of human epidermal growth factor receptor 2 [HER2/neu] protein) that has spread
to other places in the body. Trametinib and Akt inhibitor GSK2141795 may stop the growth of
tumor cells by blocking some of the enzymes needed for cell growth.